
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has shown a positive trajectory in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units in Q2, indicating growing demand for its myoelectric orthosis products. The company's strategic focus on redirecting growth within the orthotics and prosthetics (O&P) market, which is projected to contribute approximately 22% of revenue in 2024, positions it favorably amidst the expanding Medicare market. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services (CMS) to include the MyoPro under Medicare Part B benefits significantly enhances the company's market potential, suggesting robust long-term growth opportunities.
Bears say
Myomo Inc has significantly lowered its 2025 revenue guidance, revising expectations from $50–53 million down to $40–42 million. The company's marketing efforts and pipeline quality have underperformed, resulting in decreased lead quality and conversion rates, which further diminishes near-term revenue prospects. Additionally, the insurance-authorized backlog has declined from 272 in Q4 to 208, signaling a concerning trend in demand for its myoelectric orthosis products.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares